NanoBio Receives Grant to Develop an Intranasal Vaccine for RSV
No approved vaccine exists today for RSV, which results in an estimated 900,000 hospitalizations annually in the U.S. and Europe
ANN ARBOR, Mich. -- NanoBio Corporation announced today that it has received a $6M grant from the Bill & Melinda Gates Foundation to support the development of a safe and effective intranasal vaccine for Respiratory Syncytial Virus (RSV).
RSV is a highly contagious viral disease and is one of the most common causes of bronchiolitis and pneumonia. It is the number one cause of childhood hospitalization both in the United States and around the world. Nearly all children are infected with the virus at least once by the age of 2-3 years. The disease is particularly dangerous for premature babies, children with other health conditions and the elderly. Many children develop persistent pulmonary disease and/or asthma that persists throughout adult life making them susceptible to re-infection as adults. Currently, there are no approved vaccines for RSV.
To read the full press release, visit the NanoBio Corporation web site.